Orphazyme's Arimoclomol Disappoints For Muscle-Wasting Disorder
Pivotal Trial Failure For ‘Pipeline-In-A-Product’
Executive Summary
The Danish biotech's stock sank after arimoclomol failed in a Phase II/III trial for inclusion body myositis. Orphazyme is hoping for much better news in the coming weeks as the US FDA makes its decision on the drug as a treatment for Niemann-Pick disease Type C.
You may also be interested in...
Abcuro Raises $155m Series B Round For Clinical-Stage T-Cell Depleter
The company’s fresh cash will fund readouts for lead drug candidate ABC008 from a pivotal Phase II/III trial in inclusion body myositis and from Phase I/II studies in two other rare indications.
Uncertain Future For Orphazyme After Arimoclomol Snub In Europe
The EMA's medicines evaluation committee has told Orphazyme it is unlikely to recommend approval of the rare disease drug arimoclomol when it meets at the end of March, prompting the Danish firm to assess its strategic options.
Uncertain Future For Orphazyme After EMA Snub
The EMA's medicines evaluation committee has told Orphazyme it will not approve the rare disease drug arimoclomol when it meets at the end of March, prompting the Danish firm to assess its strategic options.